Activity of 9‐nitro‐camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia
2006; Wiley; Volume: 107; Issue: 7 Linguagem: Inglês
10.1002/cncr.22186
ISSN1097-0142
AutoresAlfonso Quintás‐Cardama, Hagop M. Kantarjian, Susan O’Brien, Elias Jabbour, Francis J. Giles, Farhad Ravandi, Stefan Faderl, Sherry Pierce, Jenny Shan, Srđan Verstovšek, Jorge E. Cortés,
Tópico(s)Neutropenia and Cancer Infections
ResumoTopoisomerase I inhibitors, like topotecan, have activity in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). 9-Nitro-camptothecin (9-NC) is a new oral topoisomerase inhibitor with a good safety profile. The aims of the current study were to evaluate the activity and safety of 9-NC in MDS and CMML.Adults with a diagnosis of MDS (n = 12) and CMML (n = 32) received 9-NC 2 mg/m(2) orally daily 5 days a week, every 4 to 6 weeks.Overall, 5 (11%) patients achieved complete response (CR), 7 (16%) had a partial response (PR), and 6 (14%) had hematologic improvement (HI), for an overall response rate of 41%. The response rate was similar in MDS and CMML. Severe (Grade 3-4) side effects included nausea and vomiting (7%), diarrhea (18%), other gastrointestinal toxicities (5%), and genitourinary toxicities (12%).9-NC is active in MDS and CMML. The paucity of available therapies in CMML makes 9-NC a good candidate for further studies as a single agent, or in combination with decitabine, 5-azacitidine or cytarabine.
Referência(s)